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Background: Sedoheptulose, arabitol, ribitol, and erythritol have been identiﬁed as key diagnostic
metabolites in TALDO deﬁciency. Method: Urine from 6 TALDO-deﬁcient patients and TALDO-deﬁcient
knock-out mice were analyzed using 1H-NMR spectroscopy and GC–mass spectrometry. Results: Our data
conﬁrm the known metabolic characteristics in TALDO-deﬁcient patients. The β-furanose form was the
major sedoheptulose anomer in TALDO-deﬁcient patients. Erythronic acid was identiﬁed as a major
abnormal metabolite in all patients and in knock-out TALDO mice implicating an as yet unknown
biochemical pathway in this disease. A putative sequence of enzymatic reactions leading to the formation of
erythronic acid is presented. The urinary concentration of the citric acid cycle intermediates 2-oxoglutaric
acid and fumaric acid was increased in the majority of TALDO-deﬁcient patients but not in the knock-out
mice. Conclusion: Erythronic acid is a novel and major hallmark in TALDO deﬁciency. The pathway leading to
its production may play a role in healthy humans as well. In TALDO-deﬁcient patients, there is an increased
ﬂux through this pathway. The ﬁnding of increased citric acid cycle intermediates hints toward a disturbed
mitochondrial metabolism in TALDO deﬁciency.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Two new defects in the pentose phosphate pathway (PPP) have
recently been discovered: ribose 5-phosphate isomerase (RPI)
deﬁciency (OMIM 608611) and transaldolase (TALDO) deﬁciency
(OMIM 606003).
The ﬁrst and as yet only case of RPI deﬁciency was described by
Huck et al. [1]. The patient was a 14-year-old boy with leukoence-
phalopathy and peripheral neuropathy. Magnetic resonance spec-
troscopy (MRS) showed elevated levels of the polyols ribitol and, Gas chromatography–mass
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ll rights reserved.arabitol in the brain. Ten patients from six families with TALDO
deﬁciency are known [2–5]. The disease is associated with liver
symptoms, while other organs are affected to a variable degree [4,5].
The metabolic phenotype of this disease is characterized by increased
urinary concentrations of the polyols erythritol, arabitol, ribitol,
sedoheptitol, perseitol, the sugars sedoheptulose and mannoheptu-
lose, and sedoheptulose-7-phosphate [4,6]. Erythritol, arabitol, and
sedoheptulose have been described as most prominent diagnostic
metabolites in urine of patients.
The biochemical diagnosis of RPI and TALDO deﬁciencies relies on
ﬁnding strongly increased concentrations of polyols in body ﬂuids.
The use of LC–MS/MS, LC–MS, and GC–MS for this purpose has been
reported [7–9]. 1H-NMR spectroscopy can be used for identiﬁcation
and quantiﬁcation of proton-containing metabolites in body ﬂuids
[10]. RPI deﬁciency was diagnosed successfully by measuring high
concentrations of ribitol and arabitol in urine and cerebrospinal ﬂuid
(CSF) using NMR spectroscopy [11].
In this study, we had the opportunity to characterize urine from 6
patients with genetically conﬁrmed TALDO deﬁciency. We show
Table 1
Concentrations (μmol/mmol creatinine) of metabolites found in the urine from patients with TALDO deﬁciency.
Patient Agea Sedoheptuloseb (β-furanose) Erythronic acidb Erythritolc Ribitolc Arabitolc Oxoglutaric acidb Fumaric acidb
1 16 y 390 550 137 67 142 130 42
2d 1 m 1700 2900 1058 234 345 nd 20
3d 4 y 160 770 205 41 192 50 44
4e 3 y 290 350 217 167 253 280 8
5e 1 y 870 670 494 208 298 440 8
6 4 y 350 350 290 137 262 1090 110
R 0–3 m b40 [6] b120 58–162 [9] 7–16 [9] 27–97 [9]
R 1–2 y b10 [6] b50 76–192 [9] 9–24 [9] 52–88 [9]
R 2–6 y b10 [6] b50 55–104 [9] 8–11 [9] 32–78 [9]
R 18–80 y b10 [6] b50 19–76 [9] 2–5 [9] 10–44 [9]
R ≤5 y 30–117 [20] 4–10 [20]
R N5 y 2–95 [20] nd–4 [20]
ay, year(s), m, month(s); banalyzed by 1H-NMR; canalyzed by GC–MS; d,eSibs from 2 different families; R, Reference range; nd, not detectable.
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all TALDO-deﬁcient patients and show that this metabolite is a bio-
chemical hallmark of TALDO deﬁciency. Furthermore, resonances of
the β-furanose anomer of sedoheptulose were identiﬁed and
quantiﬁed in all urine NMR spectra of the TALDO patients.2. Materials and methods
2.1. Patients
Six patients from 4 families with TALDO deﬁciency were included
in this study (Table 1). Clinical details about patients 1–3 have been
described elsewhere (patient 1 [2], patients 2 and 3 [12]). In patientsFig. 1. Sedoheptulose puriﬁed from Sedum spectabile “Brillant”. (A) 500-MHz 1H-NMRspectrum
Subscript numbers refer to the carbon position in the molecule. Assignments “★” refer the o
sedoheptulose. Sedoheptulose anomers were present in a ratio furanose-1/furanose-2/pyranos
forms and furanose-2 and pyranose-2 are the beta forms. (C1) Mass spectrum for the peakwith
{18}, and 359{15}). Characteristic for the furanose forms is the low ratio form/z 204:m/z 217
abundance}: 73{100}, 204{62}, 147{26}, 359{22}, and 217{12}). Characteristic for the pyranos4, 5, and 6, the diagnosis TALDO deﬁciency was conﬁrmed at the
metabolite level and the molecular genetic level.
2.2. Mice
Urine from TALDO-deﬁcient “knock-out” mice was obtained from
Dr. András Perl [7].
2.3. Authentic standards
Sedoheptulose is not commercially available and was isolated from
the hybrid plant Sedum spectabile “Brillant” [13]. Leaves and stalk (70 g
wet weight) were homogenized in 100 ml water and centrifuged
through a10-kDﬁlter to removeproteins. Subsequently, theultraﬁltrate. Assignments “S” refer to themost prominent anomeric formof sedoheptulose,β-furanose.
ther anomeric forms of sedoheptulose. (B) GC proﬁle: Pooled urine spiked with puriﬁed
e-1/pyranose-2=22%:64%:8%:6%. In all likelihoods, furanose-1 and pyranose-1 are alpha
assignment furanose-2 (m/z values {relative abundance}: 73{100}, 217{45}, 147{27}, 204
[18]. (C2) Mass spectrum for the peak with assignment pyranose-2 (m/z values {relative
e forms is the high ratio form/z 204:m/z 217 [18].
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isolated preparatively by thin-layer chromatography (TLC) essentially
as described by Engelke et al. [10] and measured as a model compound
by 1H-NMR spectroscopy and GC–MS (Fig. 1A and B, respectively).
Calcium L-threonic acid, potassium D-erythronic acid, and sedo-
heptulose-7-phosphate are commercially available from TCI Chemi-
cals (Portland, USA), Carbosynth (Berkshire, UK), and Sigma-Aldrich
(St. Louis, MO, USA), respectively.
2.4. Sample preparation
The urine samples were centrifuged before analysis. A volume of
70 μl of a 20.2 mmol/l trimethylsilyl-2,2,3,3-tetradeuteriumpropionic
acid (TSP, sodium salt; Aldrich) ⋅2H2O solution was added to 700 μl of
urine as a chemical shift reference (δ=0.00) and as a lock signal. The
pH of the urine was adjusted to 2.50±0.05 with HCl. Finally, we
placed 650 μl of the sample into a 5-mm NMR tube (Wilmad Royal
Imperial; Wilmad LabGlass, USA).
2.5. One-dimensional 1H-NMR spectroscopy and 1H-1H COSY spectroscopy
The urine samples were measured at 500 MHz on a Bruker DRX
500 spectrometer essentially as described before [14]. The samples
were spun (14 Hz) during the 1Dmeasurement. Shimming of the ﬁeldTable 2
1H-NMR assignments for sedoheptulose, sedoheptulose 7-phosphate, threonic acid, and ery
Metabolite Pos
1
3
4
5
6, 7
1
3
4
5
6,7
2
3
4
2
3
4
Pos, carbon position in the molecule.
*D, doublet; M, multiplet; AB, AB system; DD, doublet–doublet.homogeneity was satisfactory when the TSP line width at half peak
height was smaller than 1 Hz. Phasing of the spectra was completed
manually, and the baseline was corrected using a cubic spline
function. Metabolite resonances were ﬁtted semi-automatically with
a Lorentzian line shape and the resulting areas were compared with
area of creatinine singlet (3.13 ppm; the N–CH3 protons) to determine
metabolite concentrations expressed as μmol/mmol creatinine.
2.6. GC–mass spectroscopy
Monosaccharides and polyols were analyzed as trimethylsilyl
derivatives by GC–MS essentially as described by Janssen et al. [9]. A
VF-01msWCOT column (20 m×0.15 mm×0.15 μm) from Varianwas
used. The method is not optimally suited for quantiﬁcation of sugar
acids.
3. Results
3.1. Sedoheptulose
The 1H-NMR spectrum of the isolated sedoheptulose in aqueous
solution at pH 2.50 shows a complex pattern of resonances deriving
from a mixture of furanose and pyranose anomers (Fig. 1A).
Resonance assignments were based on previously reported NMRthronic acid.
Multiplicity* Chemical shift (ppm)
pH 2.50 pH 7.00
AB 3.55 3.58
D 4.08 4.09
DD 4.29 4.31
M 3.75 3.77
Several 3.85–3.80 3.8
AB 3.56 3.54 [15]
D 4.08 4.06 [15]
DD 4.32 4.33 [15]
M 3.81 3.78 [15]
Several 3.92 3.93 [15]
D 4.33 4.10
M 4.07 3.98
M 3.68 3.66
D 4.32 4.10
M 3.99 3.96
M 3.69 3.66
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http://www.hmdb.ca), HMDB ID 03219) and sedoheptulose-7-phos-
phate [15] and simulatedNMR spectra of four sedoheptulose anomers:
α-furanose, β-furanose, α-pyranose, and β-pyranose (ACD/HNMR
Predictor, Advanced Chemistry Development, Toronto, Ontario,
Canada). The 1H-NMR spectrum shows that the β-furanose form of
sedoheptulose had the highest concentration of the four anomeric
forms. This is in line with observations on the anomeric forms of
sedoheptulose-7-phosphate (α-furanose/β-furanose/α-pyranose=
20%:60%:20%) [15,16]. As indicated in Fig. 1A (★), the NMR spectrum
showed smaller resonances at 4.17, 4.00, 3.94, 3.65, and 3.48 ppm
representing the other anomeric forms of sedoheptulose. 1H-NMR
assignments for the β-furanose anomer of sedoheptulose are de-
scribed in Table 2. The splitting pattern and order of shift are
comparable with sedoheptulose-7-phosphate. GC–MS analysis
showed the presence of four sedoheptulose anomerswith the furanose
anomer as the most prominent form (Fig. 1B). The furanose and
pyranose anomers were identiﬁed by their characteristic m/z frag-
ments (Fig. 1C1 and C2, respectively).
3.2. Sedoheptulose in urine
In Fig. 2D, the urine 1H-NMR spectrum (4.4–3.4 ppm) from a 1-
month-old TALDO patient is shown (Table 1, patient 2). Major
metabolites in this region are creatinine (singlet at 4.29 ppm) and
betaine (singlet at 3.97 ppm). Several unusual resonances were
observed in this region (Fig. 2D, resonances S1, S3, S4, E2, E3, and E4).
This pattern of resonances was found in the urine from all patients
with TALDO deﬁciency and was not observed in NMR spectra of urine
from 100 healthy children (age: 4 to 12 years). In TALDO deﬁciency,Fig. 2. In vitro 1H-NMR spectra (500 MHz) of urine and model compounds measured at pH
spectabile. (D) Urine of a patient with transaldolase deﬁciency (S=sedoheptulose and E=erhigh micromolar concentrations of sedoheptulose, erythritol, and
arabitol are present in the urine [4]. Comparison of the urine from
patient 2 with the spectrum of the isolated sedoheptulose shows that
the unusual resonances S were caused by the β-furanose anomer of
sedoheptulose (Fig. 2C and D). Conﬁrmation was provided by a 2D
COSY NMR experiment on the isolated sedoheptulose and the urine
sample of TALDO patient 2. Two characteristic cross peaks of
sedoheptulose with the coordinates 4.08/4.29 and 4.29/3.75 ppm
were observed in the 2-dimensional NMR urine COSY spectra of the
TALDO patients. Quantiﬁcation of β-furanose sedoheptulose was
performed on the doublet at 4.08 ppm (Fig. 2D, resonance S3) andwas
1700 μmol/mmol creatinine in patient 2. In TALDO-deﬁcient patients,
the urinary concentration of β-furanose sedoheptulose ranged
between 160 and 1700 μmol/mmol creatinine (Table 1). The other
three anomers of sedoheptulose (α-furanose, α-pyranose, and β-
pyranose) were not observed in a urine NMR spectrum of the TALDO
patients due to their low concentration and overlap by other
resonances in the region between 4.3 and 3.5 ppm. The resonances
of sedoheptulose-7P could not be observed in a 1D proton NMR
spectrum of urine of our patients due to the known low concentration
of sedoheptulose-7P in TALDO patients (2–24 μmol/mmol creatinine)
and overlap by other resonances [6].
GC–MS analysis conﬁrmed the presence of abnormally high
concentrations of sedoheptulose in the urine of all TALDO patients.
The relative abundance of its four anomeric forms was similar for all
TALDO urine samples and the sedoheptulose from Sedum spectabile
(Fig. 1B). The mass spectrum shows a characteristic ratio for m/z 204
and 217 in the furanose and the pyranose anomers (Fig. 1C; [17,18]).
The m/z 217 is caused by a strong ion RO–CH=CH–CH–O+R from
furanoid hemiacetals while them/z 204 derives from the (RO–CH–)2
+2.50. (A) Threonic acid. (B) Erythronic acid. (C) Sedoheptulose isolated from Sedum
ythronic acid. Subscript numbers refer to the carbon position in the molecule [Table 2]).
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data and the GC–MS proﬁle makes it likely that the alpha forms of
furanose and pyranose anomers have a shorter retention time on this
column than the beta forms. In the GC–MS proﬁle, the anomeric ratios
of sedoheptulose were found to be furanose/pyranose=86%:14% for
urine of TALDO patients and 92%:8% for the sedoheptulose isolated
from Sedum spectabile.
3.3. Erythritol, ribitol, and arabitol
GC–MS analysis of urine from TALDO patients shows elevated
concentrations of erythritol, ribitol, and arabitol (Table 1). The
resonances of these polyols could not be observed in either the 1D
urine spectra or the 2D COSY NMR spectra. An explanation for this is
that the protons of erythritol, ribitol, and arabitol have a high degree
of splitting [11]. Identiﬁcation and quantiﬁcation of these polyols is
further hampered by overlapping resonances from other urinary
metabolites in the region 4.0–3.5 ppm [11].
3.4. Erythronic acid
The other unknown resonances in the 1D spectrum (Fig. 2D,
resonances E2, E4, and E3) could not be explained by the metabolite
erythritol or arabitol. In order to identify resonances E, several NMR
and GC–MS experiments were performed. COSY spectra revealed that
the doublet resonance at 4.32 ppm was coupled with a resonance at
3.99 ppm. An NMR database (BRUKER, AMIX), containing spectra of
500 metabolites at various pH, revealed threonic acid as a candidate
metabolite for the doublet resonance at 4.32 ppm. GC–MS analysis
conﬁrmed the presence of a high peak (with the same molecularFig. 3. GC–MS chromatogram of urine. (A) Pooled urine spiked with erythronic acid. (B) U
erythronic acid in the urine of the TALDO patient.weight of threonic acid (MW=136)) in urine samples of the TALDO
patients. However, spiking threonic acid to the urine and 1D NMR
experiments at various pH values proved that the resonances at 4.32
and 3.99 ppm were not caused by threonic acid.
Erythronic acid is the diastereomer of threonic acid. The compound
is commercially available and was purchased at Carbosynth (Berkshire,
UK). Erythronic acid in H2O at pH 2.5 (Fig. 2B) showed resonances at
4.32 (doublet, J=4.5 Hz), 3.69 (multiplet), and 3.99 (multiplet) ppm
(Table 2). Quantiﬁcation of erythronic acid in urine samples was
performed on the single proton attached to the C2 (Fig. 2D, resonance
E2) and the TSP singlet at 0.00 ppm was used as the concentration
reference. After spiking erythronic acid to a urine sample at a level of
5.8 and 10.7 mmol/l, the recovery amounted to ±90%.
Erythronic acid in H2O at pH 2.5 (Fig. 2B) showed the same 1D and
2D resonance patterns as observed in the urine of the TALDO-deﬁcient
patients. The addition of pure erythronic acid to the urine sample of
TALDO patient 5 resulted in an increase of the doublet at 4.32 ppm.
Additionally, 1D 1H-NMR spectra of erythronic acid and the urine
sample were recorded at pH 7.0. Both spectra showed a doublet
resonance that shifted from 4.32 ppm (pH 2.50) to 4.10 ppm (pH 7.0).
These experiments conﬁrmed the occurrence of erythronic acid in
urine of TALDO-deﬁcient patients. The erythronic acid concentration
ranged between 350 and 2900 μmol/mmol creatinine in the TALDO-
deﬁcient patients. In a control group of 100 healthy children (age: 4 to
12 years), we never found erythronic acid levels higher than 50 μmol/
mmol creatinine, in line with results reported by Guneral et al. [19].
In the urine from three newborns (age: 3 to 5 days), higher values
up to 150 μmol/mmol creatinine were found. Thus, erythronic acid
occurs as a regular metabolite at low micromolar concentration in
urine samples.rine of patient with transaldolase deﬁciency. (C) Control urine. (D) Mass spectrum of
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centrations of erythronic acid in the urine of TALDO patients. Fig. 3
shows the GC–MS chromatogram of a control urine (Fig. 3C) and urine
from TALDO patient (Fig. 3B). The retention time and the mass
spectrum of the erythronic acid peak in the urine of the TALDO
patients correspond with the model compound spiked to a pooled
urine sample (Fig. 3A).
3.5. Other metabolic abnormalities
In ﬁve out of six TALDO-deﬁcient patients, the urinary concentra-
tion of 2-oxoglutaric acid was increased, varying between 50 and
1090 μmol/mmol creatinine (reference ranges in μmol/mmol creat-
inine: ≤5 years=30–117, N5 years=2–95, adults=4–74 [20]). 2-
Oxoglutaric acid was not increased in urine samples from TALDO
patient 2. Fumaric acid was increased in four of the six TALDO patients
(patients 1, 2, 3, and 6; Table 1). The urine of patient 6 (4 years old)
showed the highest concentration of 2-oxoglutaric acid (1090 μmol/
mmol creatinine) and fumaric acid (110 μmol/mmol creatinine). The
concentrations of other metabolites from the citric acid cycle, succinic
acid and citric acid, were normal in all urine samples from the TALDO
patients. In addition, lactate was normal in all TALDO urine samples
and increased blood lactate has not been observed in these patients.
3.6. TALDO-deﬁcient “knock-out” mice
The urine from two TALDO-deﬁcient “knock-out” mice were
measured by 1D and 2D 1H-NMR spectroscopy and compared with
the urine spectra from wild-type mice (Fig. 4). The 1D spectra of the
two TALDO-deﬁcient mice showed the presence of high concentra-
tions of erythronic acid (1100 and 1700 μmol/mmol creatinine) and
of the β-furanose anomer of sedoheptulose (2300 and 3000 μmol/
mmol creatinine). These ﬁndings are consistent with the results
observed in the urine NMR spectra of the TALDO-deﬁcient patients.Fig. 4. In vitro 1H-NMR spectra (500 MHz) of urine from mice measured at pH 2.50.
(S=sedoheptulose and E=erythronic acid. Subscript numbers refer to the carbon positionThe β-anomers of sedoheptulose and erythronic acid were not
observed in the urine NMR spectra of the wild-type mice. 2-
Oxoglutaric acid and fumaric acid had a normal concentration in the
urine of TALDO-deﬁcient and wild-type mice.
4. Discussion
1H-NMR spectroscopy provides an overall view of proton-
containing metabolites present in body ﬂuids. Therefore, in vitro
NMR spectroscopy is suited to diagnose patients with inborn errors
of metabolism [10,21]. This study describes the in vitro NMR
investigations at the metabolite level on 6 patients with TALDO
deﬁciency. The 1D and 2D COSY 1H-NMR spectra from these patients
show a characteristic metabolic proﬁle, mainly due to the reso-
nances deriving from erythronic acid and the β-furanose anomer of
sedoheptulose. GC–MS analysis conﬁrmed the increased erythritol,
ribitol, and arabitol concentrations in the urine from the TALDO-
deﬁcient patients. An increased concentration of erythronic acid in
the urine of TALDO patients has not been described before. A low
concentration of erythronic acid is always observed in urine from
healthy children [19]. Our data show that on a molar basis, the
excretion of erythronic acid is comparable to the sedoheptulose
excretion. In this study, in 5 out of 6 TALDO-deﬁcient patients, the
concentration of erythronic acid in urine was higher than the
concentration of the metabolites sedoheptulose, erythritol, ribitol,
and arabitol. Therefore, erythronic acid ranks among the key
metabolic features in TALDO deﬁciency and testiﬁes a high ﬂux
through an as yet unknownmetabolic pathway. As erythronic acid is
always found in low concentration in the urine [19], the putative
pathway shown in Fig. 5 may be present in healthy volunteers as
well. The accumulation of erythronic acid in TALDO-deﬁcient
patients can putatively be explained as shown in Fig. 5. In TALDO
deﬁciency, the ﬂux through the PPP is disturbed leading to the
accumulation of sedoheptulose-7-phosphate [4]. Wamelink et al. [4](A) Urine of a control mouse. (B) Urine of a mouse with transaldolase deﬁciency
in the molecule [Table 2]).
Fig. 5. Pentose phosphate pathway. Transaldolase deﬁciency (solid black square) results in accumulation of sedoheptulose, erythritol, and erythronic acid. (1) Transaldolase.
(2) Sedoheptulokinase. (3) Cytosolic phosphatase. (4) Fructokinase. (5) Aldolase B. (6) Aldehyde reductase. (7) Putative (after Hauschildt et al. [23]). (8) Glyceraldehyde 3-
phosphate dehydrogenase [24,25]. (9) Phosphatase. (10) Putative [26]. (11) Transketolase. (12) D-Ribulose 5-phosphate epimerase. (13) Ribose 5-phosphate isomerase.
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further metabolized into sedoheptulose as a detoxiﬁcation process.
Sedoheptulose can further be metabolized to erythrose via the
enzymes fructokinase and aldolase (Fig. 5, enzymes 4 and 5 [22]).
Subsequently, erythrose can be reduced to erythritol, which is found
in high concentration in the urine of TALDO-deﬁcient patients. Al-
ternatively, erythrose may be phosphorylated into erythrose-4-
phosphate as shown in Fig. 5, step 7 [23]. Erythrose-4-phosphate
can be a substrate for transaldolase in some cell types. In addition,
erythrose-4-phosphate is a known substrate for glyceraldehyde 3-
phosphate dehydrogenase, converting it to 1,4-bis-phosphor-erythronate
or to 4-phosphoerythronate [24,25]. In patients with TALDO deﬁciency,
the ﬂux through this enzymatic reaction will increase. The next
step in the formation of erythronic acid is most probably a dephos-
phorylation by one of the “non-speciﬁc” phosphatases that are present
in all cells. Erythrose may also be converted to erythronic acid via
lactone formation (Fig. 5, step 10) in a similar way as D-galactose
can be converted in galactosemia patients via D-galactono-lactone to D-
galactonic acid. Conﬁrmation of the pathway leading to erythronic
acid by further experiments is required [26]. The availability of
TALDO knock-out mice is an advantage in this respect.
In almost all TALDO-deﬁcient patients, urinary fumaric acid and 2-
oxoglutaric acid were elevated while lactate and other metabolites
from the citric acid cycle such as succinic acid and malic acid were
normal. The mechanism behind this accumulation of speciﬁc citric
acid cycle intermediates remains to be elucidated. Via D-glyceralde-
hyde 3-phosphate, an intermediate of the glycolysis, an increased ﬂux
through the glycolysis toward the citric acid cycle may occur in
TALDO-deﬁcient patients. However, this would only lead to accumu-
lating citric acid cycle intermediates when there is uncoupling of the
citric acid cycle and the respiratory chain or when there is direct
inhibition of speciﬁc citric acid cycle enzymes. The observation of
increased citric acid cycle intermediates is of potential clinical
interest. As yet hyperlactacidemia has not been observed in TALDO
deﬁciency and to our knowledge extensive testing of the respiratorychain in muscle or liver of the patients has not been performed.
Hanczko et al., however, did ﬁnd evidence for mitochondrial
dysfunction and oxidative stress in the liver of TALDO knock-out
mice characterized by low NADPH, low glutathione, low ATP/ADP
ratio, and accumulation of lipid hydroperoxides [27]. Our observa-
tions may be a starting point for further studies on mitochondrial
aspects in human TALDO deﬁciency.
In conclusion, we have shown that NMR spectroscopy of urine can
be used to diagnose patients with TALDO deﬁciency. The high urinary
concentration of erythronic acid in TALDO patients has not been
reported before andmay serve as a new diagnostic hallmark of TALDO
deﬁciency.
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